NASDAQ:DARE - Dare Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.08 +0.09 (+9.09 %)
(As of 08/19/2018 04:00 PM ET)
Previous Close$1.08
Today's Range$0.9978 - $1.12
52-Week Range$0.74 - $3.60
Volume1.08 million shs
Average Volume722,713 shs
Market Capitalization$12.79 million
P/E Ratio-0.87
Dividend YieldN/A
Beta2.7
Dare Bioscience logoDaré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. The company has license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company was incorporated in 2005 and is headquartered in La Jolla, California.

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DARE
CUSIPN/A
Phone858-926-7655

Debt

Debt-to-Equity RatioN/A
Current Ratio19.92
Quick Ratio19.92

Price-To-Earnings

Trailing P/E Ratio-0.87
Forward P/E Ratio-0.86
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash Flow$0.5538 per share
Price / Cash1.95
Book Value$2.20 per share
Price / Book0.49

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-11,500,000.00
Net MarginsN/A
Return on Equity-108.49%
Return on Assets-96.80%

Miscellaneous

Employees5
Outstanding Shares11,420,000
Market Cap$12.79 million

Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions

What is Dare Bioscience's stock symbol?

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How were Dare Bioscience's earnings last quarter?

Dare Bioscience Inc (NASDAQ:DARE) released its earnings results on Monday, August, 13th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.09. View Dare Bioscience's Earnings History.

When is Dare Bioscience's next earnings date?

Dare Bioscience is scheduled to release their next quarterly earnings announcement on Monday, August, 20th 2018. View Earnings Estimates for Dare Bioscience.

What price target have analysts set for DARE?

2 brokers have issued 12-month target prices for Dare Bioscience's stock. Their predictions range from $3.00 to $6.00. On average, they anticipate Dare Bioscience's stock price to reach $4.50 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View Analyst Price Targets for Dare Bioscience.

What is the consensus analysts' recommendation for Dare Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dare Bioscience.

Who are some of Dare Bioscience's key competitors?

Who are Dare Bioscience's key executives?

Dare Bioscience's management team includes the folowing people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 51)
  • Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 59)
  • Dr. David Friend, Chief Scientific Officer
  • Mr. John Fair, Chief Bus. Officer
  • Ms. Mary Jarosz, Global Head of Regulatory Affairs

Has Dare Bioscience been receiving favorable news coverage?

News stories about DARE stock have trended somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dare Bioscience earned a media and rumor sentiment score of 0.20 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 48.06 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Dare Bioscience.

How do I buy shares of Dare Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dare Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.08.

How big of a company is Dare Bioscience?

Dare Bioscience has a market capitalization of $12.79 million. The biotechnology company earns $-11,500,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.

How can I contact Dare Bioscience?

Dare Bioscience's mailing address is 11119 NORTH TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]


MarketBeat Community Rating for Dare Bioscience (NASDAQ DARE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  343
MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe DARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel